basal insulin peglispro: Clinical Trials

12 trials of basal insulin peglispro, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 1 withdrawn. 6 Phase 1, 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 16Completed 6
Phase 36Completed 5, Withdrawn 1

Follow basal insulin peglispro: new trials by email Literature Review of basal insulin peglispro trials Research Report on basal insulin peglispro

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of LY3192767 in Healthy Participants
LY3192767, Basal Insulin Peglispro, Insulin Glargine - Healthy
Phase 1CompletedEli Lilly and Company572017-03-062019-04-05
A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus
Insulin Peglispro, Insulin Glargine - Diabetes Mellitus, Type 2
Phase 3WithdrawnEli Lilly and Company2015-02-012016-03-28
A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics
Insulin Peglispro, Insulin Glargine, Insulin Lispro - Diabetes Mellitus, Type 2
Phase 1CompletedEli Lilly and Company242014-07-012018-11-01
A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements
Insulin Peglispro, Insulin Lispro, Insulin Glargine - Diabetes Mellitus, Type 1
Phase 1CompletedEli Lilly and Company282014-06-012019-03-01
A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes
Insulin Peglispro, Insulin Glargine - Type 2 Diabetes Mellitus
Phase 3CompletedEli Lilly and Company682014-05-012019-09-18
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
Insulin Peglispro, Human Insulin - Diabetes Mellitus, Type 1
Phase 1CompletedEli Lilly and Company242014-04-012019-03-06
A Study of Insulin Peglispro in Healthy Male Japanese Participants
Insulin Peglispro - Healthy Volunteers
Phase 1CompletedEli Lilly and Company112013-12-012018-10-19
A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes
Insulin Peglispro, Insulin Glargine - Diabetes Mellitus, Type 1
Phase 1CompletedEli Lilly and Company152013-10-012019-03-11
A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment
Insulin Peglispro, Insulin Glargine, Oral Antihyperglycemic Medications (OAMs) - Type 2 Diabetes Mellitus
Phase 3CompletedEli Lilly and Company3882013-07-012019-03-15
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
LY2605541, Insulin Lispro - Type 1 Diabetes Mellitus
Phase 3CompletedEli Lilly and Company2122013-02-012018-04-20
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
LY2605541, Insulin glargine - Diabetes Mellitus, Type 2
Phase 3CompletedEli Lilly and Company4662012-05-012018-04-20
A Study in Participants With Type 2 Diabetes Mellitus
LY2605541, Insulin Glargine, Insulin Lispro - Diabetes Mellitus, Type 2
Phase 3CompletedEli Lilly and Company13692011-12-012018-04-17

Conditions studied

Diabetes Mellitus, Type 2 (6)  ·  Diabetes Mellitus, Type 1 (4)

Sponsors

Eli Lilly and Company (12)

Countries

United States (6)  ·  Germany (5)  ·  Japan (3)  ·  Puerto Rico (3)  ·  Austria (2)  ·  Czechia (2)  ·  Denmark (2)  ·  Greece (2)  ·  Israel (2)  ·  Romania (2)  ·  Russia (2)  ·  Spain (2)  ·  Taiwan (2)  ·  Australia (1)  ·  Brazil (1)

Results publications

PMID 36542287, PMID 26577417, PMID 28417532, PMID 28587667, PMID 29167192

NIH funding

2016 (1)